+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cellular interplay in pulmonary arterial hypertension: implications for new therapies



Cellular interplay in pulmonary arterial hypertension: implications for new therapies



Biochimica et Biophysica Acta 1843(5): 885-893



Pulmonary arterial hypertension (PAH) is a complex and multifactorial disease characterized by vascular remodeling, vasoconstriction, inflammation and thrombosis. Although the available therapies have resulted in improvements in morbidity and survival, PAH remains a severe and devastating disease with a poor prognosis and a high mortality, justifying the need of novel therapeutic targets. An increasing number of studies have demonstrated that endothelial cells (ECs), smooth muscle cells (SMCs) and fibroblasts of the pulmonary vessel wall, as well as platelets and inflammatory cells have a role in PAH pathogenesis. This review aims to integrate the interplay among different types of cells, during PAH development and progression, and the impact of current therapies in cellular modulation. The interplay among endothelial cells, smooth muscle cells and fibroblasts present in pulmonary vessels wall, platelets and inflammatory cells is regulated by several mediators produced by these cells, contributing to the pathophysiologic features of PAH. Current therapies are mainly focused in the pulmonary vascular tone and in the endothelial dysfunction. However, once they have not been effective, novel therapies targeting other PAH features, such as inflammation and platelet dysfunction are emerging. Further understanding of the interplay among different vascular cell types involved in PAH development and progression can contribute to find novel therapeutic targets, decreasing PAH mortality and morbidity in the future.

(PDF emailed within 0-6 h: $19.90)

Accession: 051986044

Download citation: RISBibTeXText

PMID: 24491811

DOI: 10.1016/j.bbamcr.2014.01.030


Related references

Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies. Pharmacology & Therapeutics 165: 50-62, 2016

Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. Xenobiotica; the Fate of Foreign Compounds in Biological Systems: 1-23, 2018

Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 142(5): 1150-1157, 2013

Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Current Opinion in Cardiology 23(6): 545-554, 2008

Systemic sclerosis related pulmonary hypertension associated with interstitial lung disease Impact of pulmonary arterial hypertension therapies. 2011

Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation 128(5): 475-476, 2013

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129(1): 57-65, 2014

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. Journal of Heart and Lung Transplantation 34(3): 356-361, 2015

Comparison of Oryza sativa and Oryza brachyantha genomes reveals selection-driven gene escape from the centromeric regions. Plant Cell, 2018

Letter by Bertoletti et al regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E108-E108, 2014

Letter by Ogawa and Matsubara regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E109-E109, 2014

Letter by Suissa and GaliƩ regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation 130(12): E107-E107, 2014

Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Women's Health 6(2): 285-296, 2010

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011